Paul Bonanos

Director of Biopharma Intelligence, BioCentury

san francisco, california, united states

Publications:

Is this you?

Claim your profile to connect with sources, showcase your work, and earn extra income just by writing great stories.

About

Seasoned journalist, writer, and editor with deep expertise in creating informative, engaging content. Specialties: content strategy, technical writing, journalism, trendspotting, features, PR relations, thought leadership, editorial, media outreach Market focus: biotechnology, music, publishing

Featured Articles

Private biotechs draw $2B in huge fundraising week: Venture Report

ARTICLE | Finance Private biotechs draw $2B in huge fundraising week: Venture Report Megarounds for seven start-ups amid torrent of cash ahead of industry conference January 10, 2026 1:56 AM UTC The short period between the holiday season and the start of... See more

biocentury.com•Paul Bonanos•Jan 10, 2026

Warm welcome for Aktis could open up IPO queue: Public Equity Report

Warm welcome for Aktis could open up IPO queue: Public Equity Report Plus: Basket of follow-ons draws $2B+ for seven companies NASDAQ’s first biotech IPO of 2026 was an auspicious sign among expectations that the year will bring a rebound for the sector. ... See more

biocentury.com•Paul Bonanos•Jan 10, 2026

Lilly acts on 'expansion plans' in neuroscience, immunology via $1.2B Ventyx takeout

ARTICLE | Deals Lilly acts on ‘expansion plans’ in neuroscience, immunology via $1.2B Ventyx takeout Pair of NLRP3 programs appear to drive the deal, with potential in pericarditis, Parkinson’s and obesity-associated cardiometabolic disease January 7, 202... See more

biocentury.com•Paul Bonanos•Jan 7, 2026

Amgen adds AML candidate in deal for U.K.-based Dark Blue: Deals Report

ARTICLE | Deals Amgen adds AML candidate in deal for U.K.-based Dark Blue: Deals Report Plus: Sanofi, Earendil in second tie-up; AbbVie takes option to trispecific from China-based Zelgen; and more January 7, 2026 12:17 AM UTC The year’s first full week b... See more

biocentury.com•Paul Bonanos•Jan 7, 2026

Insilico's big gain after Hong Kong listing: Finance Report

Insilico’s big gain after Hong Kong listing: Finance Report Plus: Radiopharma play Aktis looks to NASDAQ for IPO, and more As 2025 came to a close, Insilico priced the biggest Hong Kong IPO of the year by a biotech, raising nearly HK$3.3 billion ($292.6 m... See more

biocentury.com•Paul Bonanos•Jan 2, 2026

Bylined Articles

HARO Queries

Portfolio

Is this you?

Claim your profile to connect with sources, showcase your work, and earn extra income just by writing great stories.

Claim your profile

Social Media

Pitching Guidelines

Keep it short (under 200 words)
Include credentials and links
Use subject lines with query title

Pitching Guidelines

Quick Stats

Followers

364

Articles49

Last Article3 days ago

Stats

Education

Paul Bonanos

Is this you?

About

Featured Articles

Private biotechs draw $2B in huge fundraising week: Venture Report

Warm welcome for Aktis could open up IPO queue: Public Equity Report

Lilly acts on 'expansion plans' in neuroscience, immunology via $1.2B Ventyx takeout

Amgen adds AML candidate in deal for U.K.-based Dark Blue: Deals Report

Insilico's big gain after Hong Kong listing: Finance Report

Is this you?

Social Media

Connect with journalists.

Connect with journalists.

Featured Articles

Private biotechs draw $2B in huge fundraising week: Venture Report

Warm welcome for Aktis could open up IPO queue: Public Equity Report

Lilly acts on 'expansion plans' in neuroscience, immunology via $1.2B Ventyx takeout

Amgen adds AML candidate in deal for U.K.-based Dark Blue: Deals Report

Insilico's big gain after Hong Kong listing: Finance Report

Social Media